Developer docs
API playgroundTry for free, no card

Search company profiles

Cimplrx

Full company profile

uuid0003wry

Namestring
Cimplrx
Legal namestring
CIMPLRX
Websiteurl
cimplrx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Cimplrx (legal name: CIMPLRX) is a South Korea-based private drug discovery company founded in 2017 that develops and commercializes an Explainable Artificial Intelligence (XAI) platform branded CEEK-CURE. The platform is composed of two architectural layers: CEEK (Create ExplainablE Knowledge), a user interface for analyzing and visualizing results, and CURE (Collect and Uncover RElationships), a server-side XAI engine that handles machine learning requests. CEEK-CURE is delivered as four integrated workflow modules—Target Based Hit Identification (UniProt-driven), Compound Based Hit Identification (seed-compound driven across six chemical spaces), Lead Optimization with color- and size-coded contribution explanations, and Mechanism of Action (MoA) Identification—supported by visualization tools including parallel coordinates, chord diagrams, dendrograms, heatmaps, and interactive scatter plots for structure-activity relationship analysis.

The company's stated value proposition is to compress drug development timelines from the industry-standard 10+ years to 1–2 years and reduce costs by 15–30%, a claim sourced from third-party reporting rather than audited disclosures. Cimplrx monetizes through B2B professional services and joint research agreements with pharmaceutical and biotech partners, with no public pricing model or disclosed contract values. Its named customer base spans prior collaborations with Bristol-Myers Squibb (combinatorial chemical library design and HTS data analysis), Amgen (discovery and preclinical data analysis), CHDI (medicinal chemistry CRO management), and the University of North Carolina at Chapel Hill (ML via web application); current active co-development is centered on a 2025 joint research agreement with Dong-A ST, alongside multi-party collaborations with XtalPi and Gradiant Bioconvergence targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders.

The company is privately held, headquartered at 18F, 282 Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Korea, and has raised approximately $4.4M in disclosed funding as of October 2020 from Atinum Partners, Company K Partners, and Korea Investment & Securities, with additional backing from Aventures, BNK VC, KoreAsset, and Prodigy. No patents, management team bios, headcount disclosures, or audited revenue figures were available in the input materials.

Short descriptiontext

Cimplrx is a South Korea-based private drug discovery company that builds the CEEK-CURE Explainable AI platform for pharmaceutical and biotech partners. It offers hit identification, lead optimization, and mechanism-of-action modules through B2B joint research agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, Explainable AI platform, Pharmaceutical R&D software, Computational drug design, Medicinal chemistry analytics
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers5132
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI Drug Discovery Services
TypeProfessional Services
Description

CIMPLRX provides AI-powered drug discovery services to pharmaceutical and biotech companies through joint research agreements and partnerships. The company participates in the full R&D process from candidate substance evaluation through preclinical and clinical development toward commercialization.

cimplrx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1CEEK-CURE
Description

Explainable AI platform for drug discovery. CEEK (Create ExplainablE Knowledge) is the user interface for analyzing and visualizing results, while CURE (Collect and Uncover RElationships) is the XAI engine on the server side.

cimplrx.com
Core offering1 text field

Cimplrx builds and operates CEEK-CURE, an Explainable AI (XAI) platform for drug discovery that combines a user-interface visualization layer (CEEK) with a server-side XAI engine (CURE). The platform runs supervised and unsupervised machine learning models on compound-target relationship data to perform target-based and compound-based hit identification, lead optimization, and mechanism-of-action identification for pharmaceutical and biotech partners. Cimplrx delivers these capabilities via joint research agreements with pharma/biotech companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces drug development timeline from over 10 years to 1–2 years
+1 more record
Product overview1 text field

CIMPLRX is a drug discovery company operating as a single unified platform product built around its proprietary Explainable AI (XAI) engine called CEEK-CURE. The platform consists of two core components: CEEK (Create ExplainablE Knowledge), the user interface for analysis and visualization, and CURE (Collect and Uncover RElationships), the server-side XAI engine. The platform offers four integrated modules for drug discovery workflows: Target Based Hit Identification (using UniProt IDs to design compounds), Compound Based Hit Identification (using seed compounds across 6 chemical spaces), Lead Optimization (with explainable filtering), and Mechanism of Action Identification. The platform also provides visualization tools including parallel coordinates, chord diagrams, dendrograms, heatmaps, scatter plots, and clustering/diversity analysis tools.

Product and service2 records
1CEEK-CURE Explainable AI Platform
CategoryAI Drug Discovery Platform
Description

An in-house Explainable AI platform for drug discovery offered by Cimplrx to pharmaceutical and biotech clients. CEEK (Create ExplainablE Knowledge) provides the analysis and visualization user interface, while CURE (Collect and Uncover RElationships) is the server-side XAI engine that handles machine learning requests. The platform supports target-based hit identification, compound-based hit identification, lead optimization, and mechanism-of-action identification with explainable visualizations.

2AI Drug Discovery Joint Research Services
CategoryDrug Discovery Professional Services
Description

Collaborative drug discovery services delivered to pharmaceutical and biotech partners through joint research agreements, where Cimplrx applies CEEK-CURE to discover and develop new drug candidates through the candidate evaluation, preclinical, and clinical development stages.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Dong-A ST
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dong-A ST, a Korean pharmaceutical company headquartered in Seoul, partnered with CIMPLRX for AI-based new drug development. The collaboration targets cancer, brain diseases, immune/inflammatory diseases, and CNS disorders, leveraging CIMPLRX's CEEK-CURE platform for automated drug discovery.

cimplrx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prior collaboration for Machine Learning Via Web Application development.

3Bristol-Myers Squibb
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prior collaboration for Combinatorial Chemical Library Design and HTS Data Analysis & Visualization.

cimplrx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prior collaboration for Discovery & Preclinical Data Analysis & Visualization.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prior collaboration for Medicinal Chemistry CRO Management.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with Dong-A ST and CIMPLRX in a multi-party collaboration for AI-based new drug development targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

US-based AI company partnered with Dong-A ST and CIMPLRX for AI-based new drug development, contributing AI technologies including organoid analysis, genomic big data, and automated drug discovery platforms.

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

XtalPi is an AI-driven drug discovery company combining physics-based modeling, AI, and high-throughput experimentation. It is explicitly named as a strategic partner in CIMPLRX's 2025 Dong-A ST alliance, operating in the same AI drug discovery category with overlapping target/lead-optimization capabilities.

TypeDirect peer
Description

Schrödinger provides physics-based and AI-augmented computational drug discovery software (e.g., LiveDesign) used by pharma for hit ID, lead optimization, and MoA analysis. It directly overlaps with CIMPLRX's target-based hit ID, lead optimization, and MoA modules on a platform-plus-services basis.

TypeDirect peer
Description

Exscientia is a pioneer in AI-driven small-molecule drug discovery, offering end-to-end design-to-clinic capabilities through its Centaur platform. Both firms target pharma partnerships for AI-generated candidates and compete for similar enterprise design/development deals.

TypeDirect peer
Description

Recursion combines high-throughput biology, automated wet labs, and ML foundation models for drug discovery. Its platform competes with CIMPLRX's CEEK-CURE for pharma/biotech partnerships seeking AI-native discovery engines.

TypeDirect peer
Description

Insitro applies machine learning to disease biology, target discovery, and small-molecule design through partnerships with pharma. It overlaps with CIMPLRX's discovery-platform model and targets the same enterprise buyer set.

TypeDirect peer
Description

Atomwise uses AI (AtomNet) for structure-based small-molecule hit identification and lead optimization, primarily in early-stage discovery partnerships with pharma and biotech. It is directly comparable to CIMPLRX's target-based and compound-based hit ID modules.

TypeDirect peer
Description

BenevolentAI applies AI to scientific knowledge graphs and target identification/drug discovery, offering a platform-plus-portfolio model. Its target ID and MoA-style inference work overlaps substantively with CIMPLRX's modules.

8Iambic Therapeutics
TypeEmerging player
Description

Iambic builds AI-driven platforms (e.g., NeuralPLexer, IAMBIC NIM) for structure-based drug design and target prediction. It overlaps with CIMPLRX in AI-native lead optimization and target-based design but is more focused on its own pipeline assets.

9Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs, Alphabet's commercial spin-out, applies DeepMind's protein-modeling and AI drug design capabilities to pharma partnerships. It is a broad incumbent in AI drug discovery competing for the same enterprise design-and-development budgets as CIMPLRX.

TypeEmerging player
Description

Genesis Therapeutics develops AI foundation models (e.g., Dynamic Pocket Discovery) for structure-based drug design. It is an emerging player in the same AI-led small-molecule discovery category as CIMPLRX, competing for pharma design partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cimplrx

AI Drug Discovery Softwarecimplrx.com

Cimplrx is a South Korea-based private drug discovery company that builds the CEEK-CURE Explainable AI platform for pharmaceutical and biotech partners. It offers hit identification, lead optimization, and mechanism-of-action modules through B2B joint research agreements.

What Cimplrx does

Cimplrx (legal name: CIMPLRX) is a South Korea-based private drug discovery company founded in 2017 that develops and commercializes an Explainable Artificial Intelligence (XAI) platform branded CEEK-CURE. The platform is composed of two architectural layers: CEEK (Create ExplainablE Knowledge), a user interface for analyzing and visualizing results, and CURE (Collect and Uncover RElationships), a server-side XAI engine that handles machine learning requests. CEEK-CURE is delivered as four integrated workflow modules—Target Based Hit Identification (UniProt-driven), Compound Based Hit Identification (seed-compound driven across six chemical spaces), Lead Optimization with color- and size-coded contribution explanations, and Mechanism of Action (MoA) Identification—supported by visualization tools including parallel coordinates, chord diagrams, dendrograms, heatmaps, and interactive scatter plots for structure-activity relationship analysis.

The company's stated value proposition is to compress drug development timelines from the industry-standard 10+ years to 1–2 years and reduce costs by 15–30%, a claim sourced from third-party reporting rather than audited disclosures. Cimplrx monetizes through B2B professional services and joint research agreements with pharmaceutical and biotech partners, with no public pricing model or disclosed contract values. Its named customer base spans prior collaborations with Bristol-Myers Squibb (combinatorial chemical library design and HTS data analysis), Amgen (discovery and preclinical data analysis), CHDI (medicinal chemistry CRO management), and the University of North Carolina at Chapel Hill (ML via web application); current active co-development is centered on a 2025 joint research agreement with Dong-A ST, alongside multi-party collaborations with XtalPi and Gradiant Bioconvergence targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders.

The company is privately held, headquartered at 18F, 282 Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Korea, and has raised approximately $4.4M in disclosed funding as of October 2020 from Atinum Partners, Company K Partners, and Korea Investment & Securities, with additional backing from Aventures, BNK VC, KoreAsset, and Prodigy. No patents, management team bios, headcount disclosures, or audited revenue figures were available in the input materials.

Cimplrx firmographics

Firmographics
Name
Cimplrx
Legal name
CIMPLRX
Website
https://cimplrx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Cimplrx is a South Korea-based private drug discovery company that builds the CEEK-CURE Explainable AI platform for pharmaceutical and biotech partners. It offers hit identification, lead optimization, and mechanism-of-action modules through B2B joint research agreements.
Ownership category
akta.pro rank

Cimplrx industry classification

Industry
Product category
AI Drug Discovery Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Explainable AI platform
  • Pharmaceutical R&D software
  • Computational drug design
  • Medicinal chemistry analytics

Where Cimplrx is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Cimplrx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Drug Discovery Services: CIMPLRX provides AI-powered drug discovery services to pharmaceutical and biotech companies through joint research agreements and partnerships. The company participates in the full R&D process from candidate substance evaluation through preclinical and clinical development toward commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Cimplrx product offering

Product offering

Core offering

Cimplrx builds and operates CEEK-CURE, an Explainable AI (XAI) platform for drug discovery that combines a user-interface visualization layer (CEEK) with a server-side XAI engine (CURE). The platform runs supervised and unsupervised machine learning models on compound-target relationship data to perform target-based and compound-based hit identification, lead optimization, and mechanism-of-action identification for pharmaceutical and biotech partners. Cimplrx delivers these capabilities via joint research agreements with pharma/biotech companies.

Product overview

CIMPLRX is a drug discovery company operating as a single unified platform product built around its proprietary Explainable AI (XAI) engine called CEEK-CURE. The platform consists of two core components: CEEK (Create ExplainablE Knowledge), the user interface for analysis and visualization, and CURE (Collect and Uncover RElationships), the server-side XAI engine. The platform offers four integrated modules for drug discovery workflows: Target Based Hit Identification (using UniProt IDs to design compounds), Compound Based Hit Identification (using seed compounds across 6 chemical spaces), Lead Optimization (with explainable filtering), and Mechanism of Action Identification. The platform also provides visualization tools including parallel coordinates, chord diagrams, dendrograms, heatmaps, scatter plots, and clustering/diversity analysis tools.

Differentiator

Problem solved

Functional benefit

Brands

  • CEEK-CURE: Explainable AI platform for drug discovery. CEEK (Create ExplainablE Knowledge) is the user interface for analyzing and visualizing results, while CURE (Collect and Uncover RElationships) is the XAI engine on the server side.

Products and services

  • CEEK-CURE Explainable AI Platform An in-house Explainable AI platform for drug discovery offered by Cimplrx to pharmaceutical and biotech clients. CEEK (Create ExplainablE Knowledge) provides the analysis and visualization user interface, while CURE (Collect and Uncover RElationships) is the server-side XAI engine that handles machine learning requests. The platform supports target-based hit identification, compound-based hit identification, lead optimization, and mechanism-of-action identification with explainable visualizations.
  • AI Drug Discovery Joint Research Services Collaborative drug discovery services delivered to pharmaceutical and biotech partners through joint research agreements, where Cimplrx applies CEEK-CURE to discover and develop new drug candidates through the candidate evaluation, preclinical, and clinical development stages.

Quantifiable outcome

  • Reduces drug development timeline from over 10 years to 1–2 years
  • +1 more outcomes

Companies that use Cimplrx

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Cimplrx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Cimplrx partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Dong-A STcoreStrategic or Co-development PartnerDong-A ST, a Korean pharmaceutical company headquartered in Seoul, partnered with CIMPLRX for AI-based new drug development. The collaboration targets cancer, brain diseases, immune/inflammatory diseases, and CNS disorders, leveraging CIMPLRX's CEEK-CURE platform for automated drug discovery.
  • UNC at Chapel HillminorStrategic or Co-development PartnerPrior collaboration for Machine Learning Via Web Application development.
  • Bristol-Myers SquibbminorStrategic or Co-development PartnerPrior collaboration for Combinatorial Chemical Library Design and HTS Data Analysis & Visualization.
  • AmgenminorStrategic or Co-development PartnerPrior collaboration for Discovery & Preclinical Data Analysis & Visualization.
  • CHDIminorStrategic or Co-development PartnerPrior collaboration for Medicinal Chemistry CRO Management.
  • Gradiant BioconvergencecoreStrategic or Co-development PartnerPartnered with Dong-A ST and CIMPLRX in a multi-party collaboration for AI-based new drug development targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders.
  • XtalPicoreStrategic or Co-development PartnerUS-based AI company partnered with Dong-A ST and CIMPLRX for AI-based new drug development, contributing AI technologies including organoid analysis, genomic big data, and automated drug discovery platforms.

Scale indicators2 records

Expansion highlights4 records

Cimplrx competitors and assessment

Company assessment

Direct peers

  • XtalPi: XtalPi is an AI-driven drug discovery company combining physics-based modeling, AI, and high-throughput experimentation. It is explicitly named as a strategic partner in CIMPLRX's 2025 Dong-A ST alliance, operating in the same AI drug discovery category with overlapping target/lead-optimization capabilities.
  • Schrödinger: Schrödinger provides physics-based and AI-augmented computational drug discovery software (e.g., LiveDesign) used by pharma for hit ID, lead optimization, and MoA analysis. It directly overlaps with CIMPLRX's target-based hit ID, lead optimization, and MoA modules on a platform-plus-services basis.
  • Exscientia: Exscientia is a pioneer in AI-driven small-molecule drug discovery, offering end-to-end design-to-clinic capabilities through its Centaur platform. Both firms target pharma partnerships for AI-generated candidates and compete for similar enterprise design/development deals.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology, automated wet labs, and ML foundation models for drug discovery. Its platform competes with CIMPLRX's CEEK-CURE for pharma/biotech partnerships seeking AI-native discovery engines.
  • Insitro: Insitro applies machine learning to disease biology, target discovery, and small-molecule design through partnerships with pharma. It overlaps with CIMPLRX's discovery-platform model and targets the same enterprise buyer set.
  • Atomwise: Atomwise uses AI (AtomNet) for structure-based small-molecule hit identification and lead optimization, primarily in early-stage discovery partnerships with pharma and biotech. It is directly comparable to CIMPLRX's target-based and compound-based hit ID modules.
  • BenevolentAI: BenevolentAI applies AI to scientific knowledge graphs and target identification/drug discovery, offering a platform-plus-portfolio model. Its target ID and MoA-style inference work overlaps substantively with CIMPLRX's modules.

Emerging players

  • Iambic Therapeutics: Iambic builds AI-driven platforms (e.g., NeuralPLexer, IAMBIC NIM) for structure-based drug design and target prediction. It overlaps with CIMPLRX in AI-native lead optimization and target-based design but is more focused on its own pipeline assets.
  • Genesis Therapeutics: Genesis Therapeutics develops AI foundation models (e.g., Dynamic Pocket Discovery) for structure-based drug design. It is an emerging player in the same AI-led small-molecule discovery category as CIMPLRX, competing for pharma design partnerships.

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs, Alphabet's commercial spin-out, applies DeepMind's protein-modeling and AI drug design capabilities to pharma partnerships. It is a broad incumbent in AI drug discovery competing for the same enterprise design-and-development budgets as CIMPLRX.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cimplrx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cimplrx leadership team

Management profile

Number of profiles

Cimplrx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cimplrx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cimplrx

What does Cimplrx do?

Cimplrx builds and operates CEEK-CURE, an Explainable AI (XAI) platform for drug discovery that combines a user-interface visualization layer (CEEK) with a server-side XAI engine (CURE). The platform runs supervised and unsupervised machine learning models on compound-target relationship data to perform target-based and compound-based hit identification, lead optimization, and mechanism-of-action identification for pharmaceutical and biotech partners. Cimplrx delivers these capabilities via joint research agreements with pharma/biotech companies.

Is Cimplrx a public or private company?

Cimplrx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cimplrx founded?

Cimplrx was founded in 2017. It employs 11 to 50 people.

Where is Cimplrx based?

Cimplrx is headquartered in Seoul, South Korea, in the Asia region.

How does Cimplrx make money?

One revenue line is on record: AI Drug Discovery Services.

Who are Cimplrx's main competitors?

Direct peers on record are XtalPi, Schrödinger, Exscientia, Recursion Pharmaceuticals, Insitro, Atomwise and BenevolentAI. Emerging players are Iambic Therapeutics and Genesis Therapeutics. Isomorphic Labs is listed as a broad incumbent.

Does Cimplrx have an API?

No public API is recorded for Cimplrx.

What industry is Cimplrx in?

Cimplrx's product category is AI Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales